Approval of bimekizumab in the United States, an IL-17 A and F blocker with European approval for psoriatic arthritis. Dermatologists now have a range of choices for highly effective and safer options, both in biologics and orals.
https://www.dermatologytimes.com/view/advancements-in-psoriasis-treatments